BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 8, 2007
View Archived Issues
MAP's IPO Prices Lower Than Expected But Still Raises $60M
MAP Pharmaceuticals Inc. is adding $60 million through an initial public offering to support an upcoming Phase III trial of its late-stage aerosolized products for asthma and migraine. (BioWorld Today)
Read More
Haptogen Acquisition Brings Shark Therapies To Wyeth
Read More
Academia May Be Suffering But Biotech Chugs Along
Read More
Targeting Cellular MicroRNA Can Flush HIV Out Of Hiding
Read More
Pfizer Launches Bay Area Biotech Innovation Center
Read More
Other News To Note
Read More
Clinic Roundup
Read More